This global patient registry is being conducted to characterize the natural history and
real-world clinical management of patients with AHP, and to further characterize the
real-world safety and effectiveness of givosiran and other approved AHP therapies.

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

Givosiran

Clinical Trial Site

ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)

Selected events of interest are defined as hepatic events (including hepatic neoplasia),
renal events, thromboembolic events, and pancreatitis.

Porphyria attacks are defined as meeting all of the following criteria: an acute episode
of neurovisceral pain in the abdomen, back, chest, extremities and/or limbs, no other
medically determined cause, and requires treatment with intravenous (IV) dextrose or
hemin, carbohydrates, or analgesics, or other medications such as antiemetics at a dose
or frequency beyond the participant's usual daily porphyria management.

S-12 V2 is a 12-question measure capturing global quality of life and overall health
status and evaluates the following 8 domains: physical functioning, role physical, bodily
pain, general health, vitality, social functioning, role emotional, and mental health.

Patients with a diagnosis of AHP will be eligible for the study and will be managed and
treated per routine clinical practice.